IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Lonza Joins DSM as Manufacturer of Biopharma Drug for Agennix

4:02 AM MDT | April 12, 2012 | Alex Scott

Lonza has agreed to supply Agennix (Heidelberg, Germany), a biotech firm, with commercial quantities of talactoferrin, Agennix’s trial drug for the treatment of non-small cell lung cancer (NSCLC). As part of the deal, Lonza will also develop a biotech process for manufacturing the drug. Financial terms were not disclosed. Talactoferrin is an oral Dendritic Cell Mediated Immunotherapy (DCMI) drug. It is the first drug candidate of its type and currently is in phase III trials for treating NSCLC. Lonza will manufacture commercial quantities of...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa